Endo upgraded to Buy from Neutral at Citi. Citi analyst Liav Abraham upgraded Endo International to Buy from Hold, telling investors in a research note that he is moving off the sidelines. Abraham says he sees a “favorable” risk-reward profile at current levels, even after the recent upward inflection in the share price. He sees potential for an inflection in revenues in 2019 given continued execution on the base business, as well as the contribution of the Somerset acquisition.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.